Use of Fish Oils to Reduce Recurrence of Atrial Fibrillation Following DC Cardioversion

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00232219
Recruitment Status : Completed
First Posted : October 4, 2005
Last Update Posted : May 5, 2015
Information provided by (Responsible Party):
Melbourne Health

Brief Summary:

The purpose of this study is to investigate whether fish oil supplements may be beneficial in preventing the recurrence of atrial fibrillation after cardioversion.

Atrial fibrillation is a heart condition which can sometimes be successfully treated by a cardioversion.

Cardioversion involves resetting the heart back to normal with the use of electric current.

There is a tendency for the atrial fibrillation to recur , days weeks or even months after the cardioversion.

Fish oil supplements may be of benefit to patients with heart problems Recent evidence suggests that fish oils may be beneficial to patients with rhythm disturbances.

Condition or disease Intervention/treatment Phase
Atrial Fibrillation Drug: Fish oil Phase 4

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Use of Fish Oils to Reduce Recurrence of Atrial Fibrillation Following DC Cardioversion.
Study Start Date : January 2003
Actual Primary Completion Date : November 2013
Actual Study Completion Date : November 2013

Resource links provided by the National Library of Medicine

Drug Information available for: Fish oil
U.S. FDA Resources

Arm Intervention/treatment
No Intervention: Control
No fish oil exposure
Experimental: Fish oil
Patients given 6g/day of fish oil containing 1.8g/d of EPA+DHA in a 1.5:1 ratio.
Drug: Fish oil

Primary Outcome Measures :
  1. Recurrence of atrial fibrillation followed cardioversion [ Time Frame: 1 year ]

Other Outcome Measures:
  1. Safety and tolerability [ Time Frame: 1 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Patients with persistent Atrial Fibrillation on Warfarin.

Exclusion Criteria:

  • paroxysmal atrial fibrillation with self terminating episodes.
  • left atrial size>6.0cm
  • myocardial infarction in the previous 6 months.
  • contraindications to amiodarone use .
  • cardiac surgery in the previous 3 months .
  • an acute reversible illness contributing to the development of af
  • a QTc interval > 480ms.
  • pregnancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00232219

Australia, Victoria
Royal Melbourne hospital
Melbourne, Victoria, Australia, 3050
Sponsors and Collaborators
Melbourne Health
Principal Investigator: Paul Sparks, MBBS, PhD. FRACP Melbourne Health

Responsible Party: Melbourne Health Identifier: NCT00232219     History of Changes
Other Study ID Numbers: 2003.188
First Posted: October 4, 2005    Key Record Dates
Last Update Posted: May 5, 2015
Last Verified: May 2015

Additional relevant MeSH terms:
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes
Disease Attributes